473 related articles for article (PubMed ID: 32001516)
1. Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.
Singh N; Lee YG; Shestova O; Ravikumar P; Hayer KE; Hong SJ; Lu XM; Pajarillo R; Agarwal S; Kuramitsu S; Orlando EJ; Mueller KT; Good CR; Berger SL; Shalem O; Weitzman MD; Frey NV; Maude SL; Grupp SA; June CH; Gill S; Ruella M
Cancer Discov; 2020 Apr; 10(4):552-567. PubMed ID: 32001516
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.
Garcia-Prieto CA; Villanueva L; Bueno-Costa A; Davalos V; González-Navarro EA; Juan M; Urbano-Ispizua Á; Delgado J; Ortiz-Maldonado V; Del Bufalo F; Locatelli F; Quintarelli C; Sinibaldi M; Soler M; Castro de Moura M; Ferrer G; Urdinguio RG; Fernandez AF; Fraga MF; Bar D; Meir A; Itzhaki O; Besser MJ; Avigdor A; Jacoby E; Esteller M
J Natl Cancer Inst; 2022 Mar; 114(3):436-445. PubMed ID: 34581788
[TBL] [Abstract][Full Text] [Related]
3. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
[TBL] [Abstract][Full Text] [Related]
4. Reducing
Ghassemi S; Nunez-Cruz S; O'Connor RS; Fraietta JA; Patel PR; Scholler J; Barrett DM; Lundh SM; Davis MM; Bedoya F; Zhang C; Leferovich J; Lacey SF; Levine BL; Grupp SA; June CH; Melenhorst JJ; Milone MC
Cancer Immunol Res; 2018 Sep; 6(9):1100-1109. PubMed ID: 30030295
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
7. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
8. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
9. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
10. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
Thakur A; Scholler J; Schalk DL; June CH; Lum LG
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
[TBL] [Abstract][Full Text] [Related]
12. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Dufva O; Koski J; Maliniemi P; Ianevski A; Klievink J; Leitner J; Pölönen P; Hohtari H; Saeed K; Hannunen T; Ellonen P; Steinberger P; Kankainen M; Aittokallio T; Keränen MAI; Korhonen M; Mustjoki S
Blood; 2020 Feb; 135(9):597-609. PubMed ID: 31830245
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
14. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
Wei G; Hu Y; Pu C; Yu J; Luo Y; Shi J; Cui Q; Wu W; Wang J; Xiao L; Wu Z; Huang H
Ann Hematol; 2018 May; 97(5):781-789. PubMed ID: 29417201
[TBL] [Abstract][Full Text] [Related]
15. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Myers RM; Li Y; Barz Leahy A; Barrett DM; Teachey DT; Callahan C; Fasano CC; Rheingold SR; DiNofia A; Wray L; Aplenc R; Baniewicz D; Liu H; Shaw PA; Pequignot E; Getz KD; Brogdon JL; Fesnak AD; Siegel DL; Davis MM; Bartoszek C; Lacey SF; Hexner EO; Chew A; Wertheim GB; Levine BL; June CH; Grupp SA; Maude SL
J Clin Oncol; 2021 Sep; 39(27):3044-3055. PubMed ID: 34156874
[TBL] [Abstract][Full Text] [Related]
16. Bispecific CAR T-cells for B-cell Malignancies.
Furqan F; Shah NN
Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
18. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
[TBL] [Abstract][Full Text] [Related]
19. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
20. Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells.
Willier S; Raedler J; Blaeschke F; Stenger D; Pazos Escudero M; Jurgeleit F; Grünewald TGP; Binder V; Schmid I; Albert MH; Wolf A; Feuchtinger T
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
